Proportion of positive serum EBV according to the lymphoma subtype and clinical outcomes of serum EBV-positive patients.
Diagnosis | Total patients (N=263) |
EBV positive (N=79) |
CR/PR (%) | Relapse/refractory (%) | Death (%) |
---|---|---|---|---|---|
Hodgkin lymphoma | 11 | 4 (36.3) | 2 (50.0) | 2 (50.0) | 2 (50.0) |
Diffuse large B-cell lymphoma | 179 | 42 (23.5) | 40 (95.2) | 11 (26.2) | 12 (28.6) |
Follicular lymphoma | 13 | 3 (23.1) | 3 (100) | 2 (66.7) | 2 (66.7) |
Mantle cell lymphoma | 8 | 5 (62.5) | 5 (100) | 4 (80.0) | 1 (20.0) |
NK/T-cell lymphoma | 14 | 8 (57.1) | 7 (87.5) | 1 (12.5) | 2 (25.0) |
Angioimmunoblastic T-cell lymphoma | 19 | 9 (47.4) | 8 (88.9) | 3 (33.3) | 4 (44.4) |
Peripheral T-cell lymphoma | 13 | 7 (53.8) | 6 (85.7) | 3 (42.9) | 5 (71.4) |
Anaplastic large cell lymphoma | 6 | 1 (16.7) | 0 | 1 (100) | 1 (100) |
Abbreviations: CR/PR, complete response/partial response; EBV, Epstein–Barr virus; NK/T, natural killer T-cell.